Why nobody discusses the adverse psychiatric effects of chloroquine in case it might become the future treatment against COVID-19?

Chloroquine represents at least a basic prototype antimalarial drug, widely applied in several branches of medicine and also recently against a new zoonotic origin coronavirus. At present, there is little awareness of chloroquine's psychiatric side effects, which appear to be overlooked by the Scientific Committee, although they may manifest in a worryingly wide range of symptoms. This is likely to interfere with the course of specifically long-term (high-dose) COVID-19 treatment in some aggravated forms (25% of coronavirus patients were still carrying the virus 6 days after taking hydroxychloroquine).

A substrate-specific mTORC1 pathway underlies Birt-Hogg-Dubé syndrome.

The mechanistic target of rapamycin complex 1 (mTORC1) is a key metabolic hub that controls the cellular response to environmental cues by exerting its kinase activity on multiple substrates. However, whether mTORC1 responds to diverse stimuli by differentially phosphorylating specific substrates is poorly understood. Here we show that transcription factor EB (TFEB), a master regulator of lysosomal biogenesis and autophagy, is phosphorylated by mTORC1 via a substrate-specific mechanism that is mediated by Rag GTPases.

Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies.

Immune checkpoints are emerging as novel targets for cancer therapy, and antibodies against them have shown remarkable clinical efficacy with potential for combination treatments to achieve high therapeutic index. This work aims at providing a novel approach for the generation of several novel human immunomodulatory antibodies capable of binding their targets in their native conformation and useful for therapeutic applications. We performed a massive parallel screening of phage libraries by using for the first time activated human lymphocytes to generate large collections of single-chain variable fragments (scFvs) against 10 different immune checkpoints: LAG-3, PD-L1, PD-1, TIM3, BTLA, TIGIT, OX40, 4-1BB, CD27 and ICOS.